TOTAL SKIN ELECTRON BEAM IRRADIATION FOR CUTANEOUS EPIDEMIC KAPOSI'S SARCOMA (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

TOTAL SKIN ELECTRON BEAM IRRADIATION FOR CUTANEOUS EPIDEMIC KAPOSI'S SARCOMA (MEETING ABSTRACT)

The Fourth World Congress on Cancers of the Skin. April 18-20, 1991, New York, NY, 1991.. Unique Identifier : AIDSLINE ICDB/92679315
DeBlasio DS; Sherr DL; Perry DJ; Bosworth JL; North Shore Univ. Hosp., Manhasset, NY

Abstract: Epidemic Kaposi's sarcoma (EKS) is a common manifestation of AIDS, and frequently involves multiple, widespread cutaneous sites. Although limited-field radiotherapy has been useful in the management of EKS, the role of total skin electron beam (TSEB) irradiation has never been adequately assessed. Since August 1988, 13 patients (pts) with EKS have undergone TSEB irradiation at our institution. Pts were treated with linear accelerator-generated electron beams of 4 and/or 5 MeV energies utilizing either 4- or 8-field technique. Doses employed ranged from 300-2400 cGy (median 1500 cGy) delivered in 1-8 fractions. Follow-up ranged from 1 to 23 mo (median 9 mo). Of the 12 pts evaluable post-treatment, 10 experienced a significant response to TSEB irradiation, with 5 pts experiencing total regression of all lesions. The remaining 2 pts exhibited stabilization of their EKS. Ten of the 13 pts treated have died, with post-treatment survival ranging from 2-23 mo (median 9 mo). The single recurrence noted occurred 5 mo following a complete response to 600 cGy. TSEB irradiation was well tolerated, in that 8 pts experienced no significant treatment-related toxicity, 3 experienced dry desquamation and 2 experienced moist desquamation. We conclude that TSEB irradiation is a safe and effective treatment for cutaneous EKS.

Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS *Disease Outbreaks Electrons Follow-Up Studies Human Neoplasms, Multiple Primary/*RADIOTHERAPY Radiotherapy Dosage Sarcoma, Kaposi's/*RADIOTHERAPY Skin Neoplasms/*RADIOTHERAPY Whole-Body Irradiation ABSTRACT
920430
M9240937

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .